Publikationer pr. år
Publikationer pr. år
Personlig profil
Expertise
Lars Erik Kristensen is chief scientific officer (CSO) at the parker institute. He operates as part leader and part doer with the responsibility of ensuring that the scientific projects support the strategy elements of the Parker Institute.
"
Primære forskningsområder
Lars Erik Kristensens’ current research activities are focused around efficacy and tolerability of anti-TNF treatment and other 2nd generation biologicals in chronic arthritis both in controlled trial settings and observational cohort studies.
Aktuel forskning
Over the recent years, especially spondylarthritis have been studied also from an epidemiologic perspective. Exploring different outcome measures have gained increasing focus addressing interventions from a patient, societal, and clinical perspective.
Eksterne ansættelser
Københavns Universitet
2005 → …
Fingeraftryk
Dyk ned i forskningsemnerne, hvor Lars Erik Kristensen er aktive. Disse emneetiketter kommer fra denne persons arbejder. Sammen danner de et unikt fingerprint.
- 1 Lignende profiler
Samarbejde og topforskningsområder i de sidste fem år
Seneste eksterne samarbejde på lande-/områdeniveau. Dyk ned i detaljerne ved at klikke på prikkerne eller
-
Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial
Poulsen, A. S., Stisen, Z. R., Skougaard, M., Christensen, R., Overgaard, A., Gudbergsen, H., Jacobsen, S., Balslev-Clausen, A. P., Henriksen, M., Kristensen, L. E. & Bliddal, H., mar. 2025, I: Osteoarthritis and Cartilage Open. 7, 1, 100562.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
Retention rate of a novel autoinjector e-Device introduced to patients with chronic arthritis treated with certolizumab pegol in clinical practice: an observational implementation study
Jørgensen, T. S., Hansen, R. L., Pouls, B., Van den Bemt, B., Sjöwall, C. & Kristensen, L. E., jan. 2025, I: Scandinavian Journal of Rheumatology. 54, 1, s. 25-32 8 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study
Hansen, R. L., Jørgensen, T. S., Egeberg, A., Rosenø, N. A. L., Skougaard, M., Stisen, Z. R., Dreyer, L. & Kristensen, L. E., 3 maj 2024, I: Rheumatology (Oxford, England). 63, 6, s. 1593-1598 6 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
1 Citationer (Scopus) -
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
Kristensen, L. E., Tillett, W., Nash, P., Coates, L. C., Mease, P. J., Ogdie, A., Gisondi, P., Ink, B., Prickett, A. R., Bajracharya, R., Taieb, V., Lyris, N., Lambert, J. & Walsh, J. A., 2024, I: Therapeutic Advances in Musculoskeletal Disease. 16, s. 1759720X241288071Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
McGonagle, D., Kavanaugh, A., McInnes, I. B., Kristensen, L. E., Merola, J. F., Strober, B., Bolce, R., Lisse, J., Pustizzi, J., Sapin, C. & Ritchlin, C., 1 nov. 2024, I: Rheumatology (Oxford, England). 63, 11, s. 3115-3123 9 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
5 Citationer (Scopus)